Abstract: Methods for producing Fabs and IgG bi-specific antibodies comprising expressing nucleic acids encoding designed residues in the CH1/CL interface are provided. Also provided are Fabs and IgG bi-specific antibodies produced according to the provided methods as well as nucleic acids, vectors and host cells encoding the same.

Abstract: In preferred embodiments, a short circuit protection system for a wide-band gap power electronics converter composed of multiple half-bridge legs is presented. The main approaches of the system are a single point of monitoring (SPM) for multiple switching legs, and non-invasive implementation and fast speed of the short circuit current detection. Ultra-high frequency (UHF) AC current, tens or hundreds of MHz, flowing through the DC-link capacitors represents the short circuit current occurred at the multiple switching legs. To capture the UHF AC current, a non-invasive MHz bandwidth magnetic current sensor is applied to the PCB conduction path of the converter. In this digest, simulation results of the short circuit current representation through the DC-link network and the magnetic field distribution in PCB layout for the selection of the proper location of the detection, and experimental results showing the UHF AC current sensing performance are presented.

Abstract: The present disclosure relates to methods of reducing accelerated blood clearance of at least one pegylated therapeutic composition in a subject suffering from a disease and in need of treatment. The methods involve administering at least one high molecular weight polyethylene glycol composition to a subject suffering from a disease. The administration of at least one high molecular weight polyethylene glycol composition can also be used to increase the circulation half-life of at least one pegylated therapeutic composition as well as restore the pharmacokinetics of the pegylated therapeutic composition in a subject having a high titer of anti-polyethylene glycol antibodies.

Abstract: Aspects of the disclosure relate to compositions and methods useful for treating Huntington's disease. In some embodiments, the disclosure provides interfering nucleic acids (e.g., artificial miRNAs) targeting the huntingtin gene (HTT) and methods of treating Huntington's disease using the same. Accordingly, in some aspects, the disclosure provides an isolated nucleic acid comprising or encoding the sequence set forth in any one of SEQ ID NOs: 1-22.

Abstract: A bassinet includes a base, a column assembly rotatably connected to the base at a first end of the column assembly, an arm rotatably connected to a second end of the column assembly, a tub frame pivotably connected to the arm, an infant tub retained within the tub frame, the infant tub including a front wall, a back wall, and two side walls and having areas of reduced height along the front wall and at least one of the side walls to provide enhanced access to the infant located within the infant tub, and an insert configured to reversibly fit within an interior of the infant tub.

Abstract: Disclosed herein are DNA amplification methods for quantifying DNA fragments of a target DNA in a sample by size. This can be used, for example, to detect tumor-derived viral DNA in blood sample and distinguish it from larger viral DNA from non-tumor sources. In particular, disclosed herein are methods of detecting, monitoring or treating a human papilloma virus (HPV)-associated malignancy in a subject that involves detecting a presence or absence of at least one circulating tumor-derived HPV DNA in a sample from the subject. Kits for accomplishing the same are also provided.

Abstract: A method for evaluating mechanical anisotropy of a material sample to determine a characteristic of the sample includes interrogating a material sample a plurality of times. Each interrogation includes: applying a force having a direction, having a coronal plane normal to the direction of the force, and having an oval or other profile with long and short axes within the coronal plane, the long axis being oriented at a specified angle from a reference direction within the coronal plane; and measuring displacement of the material sample resulting from application of the force. The interrogations are taken at different angles of orientation within the coronal plane and different portions of the material sample are interrogated. For each measurement one or more parameters are calculated for the respective angle of orientation. A degree of anisotropy of the one or more parameters is determined and used to evaluate a characteristic of the material sample.

Abstract: Compositions and methods of transplanting cells by grafting strategies into solid organs (especially internal organs) are provided. These methods and compositions can be used to repair diseased organs or to establish models of disease states in experimental hosts. The method involves attachment onto the surface of a tissue or organ, a patch graft, a “bandaid-like” covering, containing epithelial cells with supporting early lineage stage mesenchymal cells. The cells are incorporated into soft gel-forming biomaterials prepared under serum-free, defined conditions comprised of nutrients, lipids, vitamins, and regulatory signals that collectively support stemness of the donor cells. The graft is covered with a biodegradable, biocompatible, bioresorbable backing used to affix the graft to the target site. The cells in the graft migrate into and throughout the tissue such that within a couple of weeks they are uniformly dispersed within the recipient (host) tissue.

Abstract: Methods and compositions are provided for determining whether an adenocarcinoma or squamous cell carcinoma patient is likely to respond to PARP inhibitor treatment. Specifically, a method of assessing whether a patient's adenocarcinoma (AD) lung cancer subtype is terminal respiratory unit (TRU), proximal inflammatory (PI), or proximal proliferative (PP) or a patient's squamous cell carcinoma (SQ) is primitive, classical, secretory or basal is provided herein. The method entails detecting the levels of classifier biomarkers at the nucleic acid level, in an AD or SQ lung cancer sample obtained from the patient. Based in part on the levels of the classifier biomarkers, the AD lung cancer sample is classified as a TRU, PI, or PP AD sample or the SQ lung cancer sample is classified as primitive, classical, secretory or basal and a determination of whether the patient is likely to respond to PARP inhibitor treatment can be made.

Abstract: Methods for treating a CD30-positive cancer in a subject are disclosed, wherein the methods comprise administering a lymphodepleting chemotherapy and CD30-specific chimeric antigen receptor (CAR)-expressing cells.

Abstract: Provided herein are hyperbranched polyaminoglycosides, where in some embodiments, the hyperbranched polyaminoglycosides are covalently modified to store and release nitric oxide. Some embodiments pertain to methods of making and use of hyperbranched polyaminoglycosides. In some embodiments, the covalently modified hyperbranched polyaminoglycosides may be tailored to release nitric oxide in a controlled manner and are useful for eradication of both gram positive and gram negative bacteria as well as other microbes.

Abstract: The presently disclosed subject matter describes the use of fluorinated elastomer-based materials, in particular perfluoropolyether (PFPE)-based materials, in high-resolution soft or imprint lithographic applications, such as micro- and nanoscale replica molding, and the first nano-contact molding of organic materials to generate high fidelity features using an elastomeric mold. Accordingly, the presently disclosed subject matter describes a method for producing free-standing, isolated nanostructures of any shape using soft or imprint lithography technique.

Abstract: This invention is directed to AAV compositions for circular RNA expression and methods of expressing covalently closed, circular RNA.

Abstract: The present disclosure relates to methods and compositions related to Chimeric Antigen Receptors (“CARs”) and modifications to the framework sequences to eliminate tonic signaling. The compositions include modified binding members having a binding specificity to chondroitin sulfate proteoglycan 4 (CSPG4) and are stable when prepared as single chain antibody (scFv) and incorporated into CARs. The methods further include nucleic acid constructs for the expression of CSPG4 CARs, and the application of the CSPG4 CAR to therapeutic methods for the treatment of cancer. The present disclosure also relates to the modification of humanized framework sequences.

Abstract: Methods for determining the toxicity of fresh-water and marine sediments and sediment pore water containing indigenous or introduced toxicants from each as a one-time analysis and/or for analysis over a period of time are provided. The present disclosure further provides kits assembled for the afore-mentioned determination. The methods and kits can be used for analyzing sediment and pore water samples from, among other locations, all environments where species having a dormant life stage may exist including, for example, natural zooplankton.

Abstract: The invention generally relates to electrochemically active structures and methods of making thereof. More specifically, the invention relates to electrochemically active structure comprising a crystalline electride comprising a nitride or carbide of at least one of: an alkaline earth metal, a transition metal, a lanthanide metal, or a combination thereof, wherein the electride has a lattice capable of intercalating at least one ion, thereby releasing at least one electron into an external circuit; and wherein a change in lattice volume of the electride upon intercalating the at least one ion is less than about 40%. Further, methods of making these electrochemically active structures are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Heparin compounds and synthetic heparin analogues having short acting anticoagulant activity are provided. Methods of synthesizing such heparin compounds, including chemoenzymatic pathways using sulfotransferase enzymes are provided. Methods of treating subjects in need of anticoagulant activity are provided.

Abstract: The present invention provides a polyploid adeno-associated virus (AAV) capsid, wherein the capsid comprises capsid protein VP1, wherein said capsid protein VP1 is from one or more than one first AAV serotype, wherein said capsid protein VP2 is from one or more than one first AAV serotype and capsid protein VP3, wherein said capsid protein VP3 is from one or more than one second AAV serotype and wherein at least one of said first AAV serotype is different from at least one of said second AAV serotype and is different from at least one of said third AAV serotype, in any combination.

Abstract: Large molecular weight alginates which are covalently modified to store and release nitric oxide, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates may be tailored to release nitric oxide in a controlled manner and are useful for eradication of both planktonic and biofilm-based bacteria.

Abstract: The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications.